|
|Section2= |Section3= }} AZD1305 is an experimental drug candidate that is under investigation for the management and reversal of cardiac arrhythmias, specifically atrial fibrillation and flutter. ''In vitro'' studies have shown that this combined-ion channel blocker inhibits rapidly the activating delayed-rectifier potassium current (IKr), L-type calcium current, and inward sodium current (INa). ==Pathology== Atrial fibrillation (AF) is a form of cardiac arrhythmia that arises with disorganized and rapid action potentials conducted through the atria, resulting in irregular atrial contraction.〔Guyton, Arthur C., Hall, John E. (2006). Textbook of Medical Physiology (11th ed.). Philadelphia: Elsevier Saunders〕 Causes of AF include hypertension, cardiomyopathies, alcohol consumption, viral infections, and sleep apnea, which can cause AF by increasing the occurrence of early after depolarizations (EADs).〔Kang, S. (2011). Atrial fibrillation. In A.D.A.M. Medical Encyclopedia. Retrieved from http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001236/〕 EAD is an abnormal depolarization and increase in action potential frequency that occurs in cardiac myocytes before normal repolarization is complete.〔Andersson B, Abi-Gerges N, Carlsson L. The combined ion channel blocker azd1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability. Europace 2010;12:1003-10.〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「AZD1305」の詳細全文を読む スポンサード リンク
|